Olivier Govaere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivier Govaere has a total of 812 co-authors. Here are the top co-authors by number of shared publications:
Tania Roskams
Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven and University Hospitals Leuven, Leuven, Belgium
22 shared publications- Quentin M. Anstee
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
20 shared publications - Jasper Wouters
VIB Center for Brain & Disease Research, Leuven, Belgium
12 shared publications Vlad Ratziu
Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Sorbonne University, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
12 shared publicationsElisabetta Bugianesi
Department of Medical Sciences, Division of Gastro-Hepatology, A.O. Citta della Salute e della Scienza di Torino, University of Turin, Turin, Italy
9 shared publications- Hugo Vankelecom
Laboratory of Tissue Plasticity in Health and Disease, Cluster of Stem Cell and Developmental Biology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
9 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in JHEP Reports
Age-specific histological features of severe alpha-1 antitrypsin deficiency-associated liver disease (Pi*ZZ genotype) ☆
- 12 November 2026
- Published by Elsevier in JHEP Reports
Open AccessAge-specific histological features of severe alpha-1 antitrypsin deficiency-associated liver disease (Pi*ZZ genotype) ☆
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8130) , 59-75
Molecular mechanisms and pathogenesis of MASH
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8130) , 59-75
Molecular mechanisms and pathogenesis of MASH
- Top Cited Papers
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8130) , 76-91
Current therapeutic landscape and future treatment perspectives of MASH
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 657 (8130) , 76-91
Top Cited PapersCurrent therapeutic landscape and future treatment perspectives of MASH
- Top Cited PapersOpen Access
- 18 May 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (6) , 1295-1307
Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition impacting over 30% population, yet the dynamic changes in macrophage composition from steatosis to steatohepatitis (metabolic dysfunction-associated steatohepatitis, MASH) remain unclear. Here, by integrating single-nucleus transcriptomics, spatial multi-omics and proteomics on human samples, we delineate the evolving landscape of hepatic macrophages across the MASLD spectrum. Our analysis reveals a progressive depletion of Kupffer cells accompanied by the emergence of diverse, phenotypically distinct macrophage subsets. Spatial multi-omics further demonstrates that disease progression toward MASH is marked by an accumulation of antigen-presenting, phagocytic GPNMB+ macrophages, supported by IL32-producing hepatocytes. These macrophages showed an adaptive metabolic and pro-inflammatory phenotype that is tightly regulated by both spatial context and disease stage. Identified macrophage markers enable patient stratification by disease activity and its stage across independent clinical cohorts. Our study sheds light on the diversity of macrophage identities and metabolic-adaptive phenotypes during the progression of MASLD.
- 18 May 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (6) , 1295-1307
Top Cited PapersOpen AccessIntegrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition impacting over 30% population, yet the dynamic changes in macrophage composition from steatosis to steatohepatitis (metabolic dysfunction-associated steatohepatitis, MASH) remain unclear. Here, by integrating single-nucleus transcriptomics, spatial multi-omics and proteomics on human samples, we delineate the evolving landscape of hepatic macrophages across the MASLD spectrum. Our analysis reveals a progressive depletion of Kupffer cells accompanied by the emergence of diverse, phenotypically distinct macrophage subsets. Spatial multi-omics further demonstrates that disease progression toward MASH is marked by an accumulation of antigen-presenting, phagocytic GPNMB+ macrophages, supported by IL32-producing hepatocytes. These macrophages showed an adaptive metabolic and pro-inflammatory phenotype that is tightly regulated by both spatial context and disease stage. Identified macrophage markers enable patient stratification by disease activity and its stage across independent clinical cohorts. Our study sheds light on the diversity of macrophage identities and metabolic-adaptive phenotypes during the progression of MASLD.
- 20 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 449-462
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
- 20 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 449-462
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
- Open Access
- 20 August 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (6) , 1305-1319
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis
- 20 August 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (6) , 1305-1319
Open AccessClaudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis
- 13 June 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (3) , e163-e165
Reply to: “Diabetes-driven pathophysiological remodeling of mesenteric adipose tissue: Transcriptomic insights into macrophage infiltration and adipokine dyshomeostasis”
- 13 June 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (3) , e163-e165
Reply to: “Diabetes-driven pathophysiological remodeling of mesenteric adipose tissue: Transcriptomic insights into macrophage infiltration and adipokine dyshomeostasis”
- Open Access
- 6 June 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (5) , 1142-1155
Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation
- 6 June 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (5) , 1142-1155
Open AccessSteatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation
- Top Cited PapersOpen Access
- 12 June 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (6) , 1178-1196
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.
- 12 June 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (6) , 1178-1196
Top Cited PapersOpen AccessAn unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.
- Open Access
- 27 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease
Background: NAFLD is associated with activation of fibroblasts and hepatic fibrosis. Substantial patient heterogeneity exists, so it remains challenging to risk-stratify patients. We hypothesized that the amount of fibroblast activity, as assessed by circulating biomarkers of collagen formation, can define a “high-risk, high-fibrogenesis” patient endotype that exhibits greater fibroblast activity and potentially more progressive disease, and this endotype may be more amendable to dietary intervention. Methods: Patients with clinically confirmed advanced NAFLD were prescribed a very low-calorie diet (VLCD) intervention (∼800 kcal/d) to induce weight loss, achieved using total diet replacement. Serum markers of type III (PRO-C3) and IV collagen (PRO-C4) fibrogenesis were assessed at baseline every second week until the end of the VLCD, and 4 weeks post-VLCD and at 9 months follow-up. Results: Twenty-six subjects had a mean weight loss of 9.7% with VLCD. This was associated with significant improvements in liver biochemistry. When stratified by baseline PRO-C3 and PRO-C4 into distinct fibrosis endotypes, these predicted substantial differences in collagen fibrogenesis marker dynamics in response to VLCD. Patients in the high activity group (PRO-C3 >11.4 ng/mL and/or PRO-C4 >236.5 ng/mL) exhibited a marked reduction of collagen fibrogenesis, ranging from a 40%–55% decrease in PRO-C3 and PRO-C4, while fibrogenesis remained unchanged in the low activity group. The biochemical response to weight loss was substantially greater in patients a priori exhibiting a high fibroblast activity endotype in contrast to patients with low activity. Conclusions: Thus, the likelihood of treatment response may be predicted at baseline by quantification of fibrogenesis biomarkers.
- 27 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Open AccessSerum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease
Background: NAFLD is associated with activation of fibroblasts and hepatic fibrosis. Substantial patient heterogeneity exists, so it remains challenging to risk-stratify patients. We hypothesized that the amount of fibroblast activity, as assessed by circulating biomarkers of collagen formation, can define a “high-risk, high-fibrogenesis” patient endotype that exhibits greater fibroblast activity and potentially more progressive disease, and this endotype may be more amendable to dietary intervention. Methods: Patients with clinically confirmed advanced NAFLD were prescribed a very low-calorie diet (VLCD) intervention (∼800 kcal/d) to induce weight loss, achieved using total diet replacement. Serum markers of type III (PRO-C3) and IV collagen (PRO-C4) fibrogenesis were assessed at baseline every second week until the end of the VLCD, and 4 weeks post-VLCD and at 9 months follow-up. Results: Twenty-six subjects had a mean weight loss of 9.7% with VLCD. This was associated with significant improvements in liver biochemistry. When stratified by baseline PRO-C3 and PRO-C4 into distinct fibrosis endotypes, these predicted substantial differences in collagen fibrogenesis marker dynamics in response to VLCD. Patients in the high activity group (PRO-C3 >11.4 ng/mL and/or PRO-C4 >236.5 ng/mL) exhibited a marked reduction of collagen fibrogenesis, ranging from a 40%–55% decrease in PRO-C3 and PRO-C4, while fibrogenesis remained unchanged in the low activity group. The biochemical response to weight loss was substantially greater in patients a priori exhibiting a high fibroblast activity endotype in contrast to patients with low activity. Conclusions: Thus, the likelihood of treatment response may be predicted at baseline by quantification of fibrogenesis biomarkers.